507 A phase 1 clinical trial of RP2, an enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody, as a single agent and combined with nivolumab in patients with advanced solid tumors

• Anna Olsson-Brown,
• Joseph Sacco,
• Mark Middleton,
• Kevin Harrington,
• Robert Coffin,
• Andrea Pirzkall,
• Praveen Bommareddy,
• Isla Leslie,
• Francesca Aroldi,
• Pablo Nenclares,
• Tze Chan,
• Imran Saleem,
• Henry Castro

Affiliations

Anna Olsson-Brown

1 Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK

Joseph Sacco

8 Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, Wirral, UK

Mark Middleton

Aff12 grid.451056.30000000121163923National Institute for Health Research Biomedical Research Centre London UK

Kevin Harrington

Radiotherapy and Imaging, The Institute of Cancer Research, London, UK

Robert Coffin

Aff14 grid.417886.40000 0001 0657 5612Amgen Woburn MA USA

Andrea Pirzkall

Aff3 0000 0004 0534 4718grid.418158.1Genentech, Inc. South San Francisco CA USA

Praveen Bommareddy

10Replimune, Woburn, MA, USA

Isla Leslie

Head and Neck Unit, Royal Marsden Hospital NHS Trust, London, UK

Francesca Aroldi

1University of Oxford, Oxford, UK

Pablo Nenclares

Head and Neck Unit, Royal Marsden Hospital NHS Trust, London, UK

Tze Chan

4Royal Liverpool University Hospital, Liverpool, UK

Imran Saleem

5Replimune, Woburn, MA, USA

Henry Castro

5Replimune, Woburn, MA, USA